In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 drugs like Ozempic, Eli Lilly has said., Health, Times Now ...

Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every background'.

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Recent medical news supports the reasoning behind the innovative Wellness Incentive Program offered by Teachers Health Trust ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a ...

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...